These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. Newsome PN; Ambery P J Hepatol; 2023 Dec; 79(6):1557-1565. PubMed ID: 37562748 [TBL] [Abstract][Full Text] [Related]
11. The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Jakubowska A; Roux CWL; Viljoen A Endocrinol Metab (Seoul); 2024 Feb; 39(1):12-22. PubMed ID: 38356208 [TBL] [Abstract][Full Text] [Related]
12. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach. Batiha GE; Al-Kuraishy HM; Al-Gareeb AI; Ashour NA; Negm WA Inflammopharmacology; 2023 Aug; 31(4):1683-1693. PubMed ID: 37208555 [TBL] [Abstract][Full Text] [Related]
13. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097 [TBL] [Abstract][Full Text] [Related]
14. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Nauck MA; Quast DR; Wefers J; Pfeiffer AFH Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013 [TBL] [Abstract][Full Text] [Related]
15. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Mentis N; Vardarli I; Köthe LD; Holst JJ; Deacon CF; Theodorakis M; Meier JJ; Nauck MA Diabetes; 2011 Apr; 60(4):1270-6. PubMed ID: 21330636 [TBL] [Abstract][Full Text] [Related]
16. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. Xie C; Alkhouri N; Elfeki MA World J Hepatol; 2024 May; 16(5):731-750. PubMed ID: 38818288 [TBL] [Abstract][Full Text] [Related]
17. [A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists]. Scheen A Rev Med Liege; 2024 Sep; 79(9):605-612. PubMed ID: 39262368 [TBL] [Abstract][Full Text] [Related]
18. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges. Huang X; Liu J; Peng G; Lu M; Zhou Z; Jiang N; Yan Z J Endocrinol; 2024 Sep; 262(3):. PubMed ID: 38916409 [TBL] [Abstract][Full Text] [Related]
19. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism. Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834 [TBL] [Abstract][Full Text] [Related]
20. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide. Gasbjerg LS; Rosenkilde MM; Meier JJ; Holst JJ; Knop FK Diabetes Obes Metab; 2023 Nov; 25(11):3079-3092. PubMed ID: 37551549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]